Levena Biopharma, A Sorrento Company, Announces Clinical Data For Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients
Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's session saw 784 companies set new 52-week lows.
Sorrento Therapeutics Subsidiary Scilex Holding To Present SP-102 Efficacy And Safety Data From Its Pivotal Phase 3 Clinical Trial Program For Sciatica Pain Management At 24th Annual Meeting Of American Society Of Interventional Pain Physicians
Scilex Holding Company ("Scilex"), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. (NASDAQ:SRNE, ", Sorrento", )))), a commercial biopharmaceutical
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Sorrento Announces FDA Authorization To Proceed With Phase 1 Study Of Intravenous STI-9167 (COVISHIELD) Neutralization Antibody Against Omicron BA.2 And Other SARS-CoV-2 Variants Of Concern
FDA granted IND clearance today for STI-9167 (Intravenous COVISHIELD™) for a Phase 1 safety and pharmacokinetic study in healthy volunteers.
Initial trials are expected to be followed by a multinational Phase
